
|Articles|November 1, 2003
ENROLLEMENT COMPLETED
Maxim pharmaceuticals has completed enrollment for the confirmatory Phase 3 trial of its lead drug candidate Ceplene? (histamine dihydrochloride) in combination with interleukin-2 (IL-2) for the treatment of advanced malignant melanoma patients with liver metastases.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Clascoterone 5% Delivers Strong Phase 3 Hair-Growth Results
2
Top 5 Articles of the Week: November 30-December 5
3
The Weekly Roundup: December 1-5
4
DeepSeek-R1 Outperforms ChatGPT-4o in Urticaria Clinical Queries
5



















